KoBioLabs Inc
348150
Company Profile
Business description
KoBioLabs Inc is a biotechnology company focused on Microbiome therapeutics. It is involved in the research of medicines for Immune, Metabolic and Neurological Diseases.
Contact
1 Gwanak-ro, Gwanak-gu
Room 628, Building 220, Seoul National University
Seoul
KORT: +82 28889964
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
57
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,874.64 | 24.21 | 0.31% |
| DAX 40 | 24,476.31 | 235.49 | 0.97% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,152.53 | 91.04 | 1.00% |
| HKSE | 25,667.18 | 129.11 | 0.51% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |